PDGFR alpha/KIT Mutant-specific Inhibitor BLU-285
Semantic Scholar uses AI to extract papers important to this topic.
The small-molecule inhibitor BLU-285 inhibits clinically relevant KIT and PDGFRA mutations.
In a phase I trial of avapritinib (formerly BLU-285), which targets D816V mutant KIT, for the treatment of advanced systemic… (More)
Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease… (More)
for optimism: the findings of Jawhar and colleagues provide a molecular footing to help navigate the steep mountain toward cure… (More)
- Science translational medicine
Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when… (More)